Navigation Links
BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
Date:11/15/2007

BRUSSELS, Belgium and BRISBANE, Calif., Nov. 15 /PRNewswire/ -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer therapies, today announced it has initiated a Phase 2 study of its lead PARP inhibitor, BSI-201, in patients with triple-negative breast cancer that do not express the estrogen, progesterone or HER2 receptors.

The company designed the Phase 2 trial in this indication-which represents a major unmet medical need-based on molecular biomarker data presented today showing that breast tumors that are estrogen-negative and progesterone- negative were more likely to overexpress PARP, as were HER2-negative tumors. The data were presented at European Organization for Research and Treatment of Cancer-National Cancer Institute-American Society for Clinical Oncology Annual Meeting on "Molecular Markers in Cancer" in Brussels.

"Our research shows clearly that not only is PARP overexpressed in breast tumors generally, it is even more likely to be overexpressed in triple- negative tumors. That suggests that PARP inhibition may be a particularly effective way to target those hard-to-treat cancers," said BiPar Executive Vice President Barry Sherman, M.D. "Our Phase 2 trial of BSI-201 will build on those insights and, if successful, will serve as powerful proof of our strategy to use molecular biomarker data to focus our clinical studies of BiPar's PARP inhibitors on tumors that markedly upregulate PARP."

Patients with triple-negative breast cancer, who make up 10 to 15 percent of all patients, have few effective therapeutic options. Neither targeted therapies such as Herceptin and Tykerb nor anti-estrogens such as tamoxifen provide a benefit, and triple-negative tumors are associated with a high rate of relapse. Such cancers are particularly prevalent in premenopausal African- American women.

"We are very excited about being able to offer patients with triple- negative metastatic breast cancer treatment
'/>"/>

SOURCE BiPar Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
2. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
3. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
4. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
5. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
6. Enrollment Begins on Human PK Study for Medidur(TM) FA
7. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
8. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
9. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
10. Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
11. DiObex Begins Dosing Patients in Phase 2b Trial of Type 2 Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)...  HealthLoop® released an app version of its doctor-patient ... and allows people to share medical device and activity ... technologies to enhance the HealthLoop experience for iPhone users, ... doctors between visits. "This new flood ... is exciting," says HealthLoop founder Dr. Jordan Shlain ...
(Date:9/30/2014)... VIEW, Calif. , Sept. 30, 2014 /PRNewswire/ ... tissue diagnostics market, Frost & Sullivan recognizes Ventana ... Roche Group, with the 2014 North American Frost ... to strict quality practices along with a focus ... Ventana a global leader in tissue-based cancer diagnostic ...
(Date:9/30/2014)... 2014  Georgia-Pacific Professional is a leading provider ... a wide range of away from home applications. ... in healthcare, including hospitals, long-term care facilities, surgical ... its healthcare products and solutions to the dental ... of infection control in the dental office," said ...
Breaking Medicine Technology:HealthLoop Integrates with Apple's HealthKit Enabling Patients to Share Health Data with Their Doctors Right from their iPhone 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 2Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 3
... Mass., Nov. 11, 2010 Interleukin Genetics, Inc. (OTCQB: ILIU) ... ended September 30, 2010. Revenue for the three ... $0.3 million for the same period in the prior year. ... as we experience positive growth. Research and development ...
... NEW YORK, Nov. 11, 2010 /PRNewswire-Asia-FirstCall/ -- American ... ("the Company" or "AOBO"), a pharmaceutical company dedicated ... commercialization of a broad range of prescription and ... of AOBO Wujia Rongxue Oral Liquid, ("AWRO Liquid"), ...
Cached Medicine Technology:Interleukin Genetics Reports Third Quarter 2010 Financial Results 2Interleukin Genetics Reports Third Quarter 2010 Financial Results 3Interleukin Genetics Reports Third Quarter 2010 Financial Results 4Interleukin Genetics Reports Third Quarter 2010 Financial Results 5American Oriental Bioengineering Introduces Wujia Rongxue Oral Liquid 2
(Date:9/30/2014)... (PRWEB) September 30, 2014 The ... to improve breast cancer risk prediction and to ... a study published in Breast Cancer Research (BCR ... density and breast cancer risk: a case-control study ... strong connection between breast density and breast cancer ...
(Date:9/30/2014)... partners successfully established a visual mapping of the ... suppressor cells (MDSC). The damage and immune suppression ... this is a major stepping stone in creating ... factors from precursors present in hematopoietic organs such ... population of cells suppresses the activity of various ...
(Date:9/30/2014)... University of Eastern Finland shows that dietary polyunsaturated fatty ... The sources of polyunsaturated fatty acids include fish, vegetable ... Arteriosclerosis, Thrombosis & Vascular Biology , an esteemed journal ... not found an association between the consumption of saturated ... that the mere reduction of saturated fats from the ...
(Date:9/30/2014)... This two-day, advanced PT continuing education course ... may arise following a concussion or mild traumatic brain ... from sports related injuries, car accidents, falls, to the ... of returning soldiers from war zone regions. While at ... can result in similar injuries, the course will emphasize ...
(Date:9/30/2014)... By Dennis Thompson ... -- Every day, people receive medical implants -- artificial ... may not have been rigorously tested before or after their ... studies contend. The studies -- conducted by prominent nonprofit ... Medicine -- lay the blame for inadequate medical device ...
Breaking Medicine News(10 mins):Health News:Mammographic Density Offers Potential to Improve Prediction of Breast Cancer Risk and Development of Personalized Screening 2Health News:Mammographic Density Offers Potential to Improve Prediction of Breast Cancer Risk and Development of Personalized Screening 3Health News:Mammographic Density Offers Potential to Improve Prediction of Breast Cancer Risk and Development of Personalized Screening 4Health News:Dietary polyunsaturated fatty acids linked to smaller risk of coronary heart disease 2Health News:North American Seminars Presents Traumatic Brain Injury and Concussions in Conduction with St. Anthony's Medical Center in St. Louis, MO on November 8-9, 2014 2Health News:North American Seminars Presents Traumatic Brain Injury and Concussions in Conduction with St. Anthony's Medical Center in St. Louis, MO on November 8-9, 2014 3Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 2Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 3Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 4
... these patients, researcher says , , FRIDAY, Oct. 10 (HealthDay ... 75 percent higher risk for developing colorectal cancer sometime ... syndrome is a conglomeration of three or four diseases, ... illnesses, including a number of cancers," said study co-author ...
... excellence in the implementation of electronic health records (EHRs), the ... of the 2008 Davies Awards in the Organizational, Ambulatory and ... ... Chicago, IL (PRWEB) October 10, 2008 -- Honoring excellence in ...
... Mich.---The University of Michigan received $5 million from the ... resource of high-quality experimental data sets of drug-making compounds ... new level. , The resource will house the ... the effectiveness of potential new drugs, said Heather Carlson, ...
... 10 The Johns Hopkins University School,of Medicine ... Breast Cancer Strategies: From Biomarkers to Treatment,Selection," to ... advances in,breast cancer treatment., In recent years, ... to chemotherapeutic and biologic treatment combinations that are,increasingly ...
... Mobile Massage Team, (http://www.mobilemassageteam.com ), a leading ... wellness programs, promotional events, and special,affairs, announced ... area throughout,eastern Pennsylvania and the greater Philadelphia ... about the increasing interest in our on-site,seated, ...
... nationally recognized faculty will,present the very latest treatment ... course "Optimizing Adjuvant Breast Cancer,Strategies: From Biomarkers to ... It is challenging for practicing oncologists and other ... on the latest patient care,advances. This accredited course ...
Cached Medicine News:Health News:Metabolic Syndrome Raises Colon Cancer Risk 75% 2Health News:Metabolic Syndrome Raises Colon Cancer Risk 75% 3Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 2Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 3Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 4Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 5Health News:U-M to house leading drug database 2Health News:Latest Research on Breast Cancer Presented in a Virtual E-Conference CME Course 2Health News:Mobile Massage Team Announces Expansion of On-Site Seated Massage Services Throughout Eastern Pennsylvania and the Greater Philadelphia Region 2Health News:Nationally Recognized Faculty Presents Latest Advances in Care of Patients with Breast Cancer 2
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
These reusable 0.1mL PYREX serological pipets are color coded by size for easy identification and sorting. Colored graduations are enameled onto the glass. These "to deliver" (TD) pipets must be blow...
... Invisio™ Flexible CystoNephroscope (ICN) employs an ultra-miniature ... the tip of the endoscope that captures ... of the surgical site is provided by ... the endoscope. This illumination technology eliminates the ...
... These 25mL PYREX volumetric pipets were designed ... A tolerance of No. 7100 is not required. ... and length as our No. 7100, but have ... primarily due to this faster delivery that accuracy ...
Medicine Products: